This report is a TB program evaluation, which is designed to complement the general CDC Introduction to Program Evaluation for Public Health Programs manual. It contains background information, goals and objectives of a TB program, and reasons for evaluating TB prevention and control programs and explains why the CDC evaluation framework should be used.
This report provides World Health Organization (WHO) member states with guidance on preventing TB transmission in healthcare facilities, congregate settings, and households. It focuses on what to do and how to prioritize TB infection control at national levels and includes recommendations for national managerial activities. The report updates or presents new or increased emphasis on the particular administrative and environmental controls to be implemented and on personal protective equipment. It includes a special focus on building design and use of space.
This information sheet discusses preventing occupational transmission of TB by means of an infection control program. It explains the three levels of TB infection control in health care settings: (1) administrative controls to minimize areas where exposure may occur; (2) environmental controls to reduce the concentration of airborne TB bacteria; and (3) respiratory protective equipment to be used in situations that pose a high risk of exposure.
This information sheet discusses the need for individuals with latent TB infection (LTBI) to get treatment and prevent the progression of LTBI to TB disease. It emphasizes the importance of the health care provider communicating the value of LTBI treatment and of identifying barriers to adherence. The information sheet also lists strategies for maximizing adherence including collaborating with community agencies and partnering with local health departmetns and community based organizations that can provide needed resources.
This information sheet discusses the bacille Calmette-Guerin (BCG) vaccine for TB disease, which is used in many countries to prevent childhood tuberculous meningitis and miliary disease. It explains why the BCG is not generally recommended for use in the United States; suggests that the BCG should be considered under specific circumstances; and provides recommendations for when the BCG should be used with children and health care workers and contraindications when it should not be used, such as for immunosuppressed persons and pregnant women.
Using a question-and-answer format, this pamphlet provides general information about TB, including transmission, symptoms, and the difference between TB infection and disease. The pamphlet explains both a blood and skin test, the procedures that are followed if the test result is negative or positive, and treatment for both TB infection and TB disease.
The Stop TB poster can be used by TB programs and other healthcare settings to help educate people with TB, as well as people at risk for TB. The poster describes how TB is spread, explains the difference between latent TB infection and TB disease, includes symptoms of active TB disease, and highlights the importance of completing TB treatment to help stop TB.
This fact sheet discusses TB and how it is affected by the HIV. It defines TB and explains the difference between TB infection and latent TB infection. The fact sheet advises that HIV weakens the immune system increasing the chance that in people with HIV and latent TB, the TB germs will become active and attack the body causing TB disease. It emphasizes the importance of TB treatment and taking the TB drugs as prescribed.
